SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Iovance Biotherapeutics, Inc. – ‘10-Q’ for 6/30/20 – ‘R7’

On:  Thursday, 8/6/20, at 5:16pm ET   ·   For:  6/30/20   ·   Accession #:  1104659-20-91526   ·   File #:  1-36860

Previous ‘10-Q’:  ‘10-Q’ on 5/5/20 for 3/31/20   ·   Next:  ‘10-Q’ on 11/5/20 for 9/30/20   ·   Latest:  ‘10-Q’ on 5/9/24 for 3/31/24   ·   9 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/06/20  Iovance Biotherapeutics, Inc.     10-Q        6/30/20   63:7.7M                                   Toppan Merrill/FA

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.27M 
 2: EX-10.3     Material Contract                                   HTML     38K 
 3: EX-10.4     Material Contract                                   HTML     51K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
 7: EX-32.2     Certification -- §906 - SOA'02                      HTML     20K 
14: R1          Document And Entity Information                     HTML     71K 
15: R2          Condensed Consolidated Balance Sheets               HTML     90K 
16: R3          Condensed Consolidated Balance Sheets               HTML     40K 
                (Parenthetical)                                                  
17: R4          Condensed Consolidated Statements of Operations     HTML     40K 
18: R5          Condensed Consolidated Statements of Comprehensive  HTML     29K 
                Loss                                                             
19: R6          Condensed Consolidated Statements of Stockholders'  HTML     80K 
                Equity                                                           
20: R7          Condensed Consolidated Statements of Cash Flows     HTML     84K 
21: R8          General Organization and Business                   HTML     29K 
22: R9          Summary of Significant Accounting Policies          HTML    143K 
23: R10         Cash Equivalents and Short-Term Investments         HTML    108K 
24: R11         Balance Sheet Components                            HTML     37K 
25: R12         Stockholders' Equity                                HTML     30K 
26: R13         Stock Based Compensation                            HTML     71K 
27: R14         Licenses and Agreements                             HTML     38K 
28: R15         Legal Proceedings                                   HTML     37K 
29: R16         Leases                                              HTML    141K 
30: R17         Related Party Transactions                          HTML     22K 
31: R18         Subsequent Event                                    HTML     21K 
32: R19         Summary of Significant Accounting Policies          HTML    173K 
                (Policies)                                                       
33: R20         Summary of Significant Accounting Policies          HTML    127K 
                (Tables)                                                         
34: R21         Cash Equivalents and Short-Term Investments         HTML    108K 
                (Tables)                                                         
35: R22         Balance Sheet Components (Tables)                   HTML     36K 
36: R23         Stock Based Compensation (Tables)                   HTML     64K 
37: R24         Leases (Tables)                                     HTML    129K 
38: R25         General Organization and Business (Details)         HTML     44K 
39: R26         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash,  HTML     38K 
                Cash equivalents and Restricted Cash (Details)                   
40: R27         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Loss   HTML     28K 
                per share (Details)                                              
41: R28         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair   HTML     25K 
                value (Details)                                                  
42: R29         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     23K 
                Stock-based compensation expense (Details)                       
43: R30         SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -        HTML     23K 
                Stock-based compensation by instrument (Details)                 
44: R31         Cash Equivalents and Short-Term Investments         HTML     26K 
                (Details)                                                        
45: R32         Cash Equivalents and Short-Term Investments -       HTML     23K 
                Short-term investments (Details)                                 
46: R33         CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Cost  HTML     33K 
                and fair value (Details)                                         
47: R34         Balance Sheet Components (Details)                  HTML     34K 
48: R35         Stockholders' Equity (Details)                      HTML     90K 
49: R36         STOCK BASED COMPENSATION - Stock Options (Details)  HTML     59K 
50: R37         STOCK BASED COMPENSATION - Assumptions (Details)    HTML     31K 
51: R38         STOCK BASED COMPENSATION - Additional information   HTML    104K 
                (Details)                                                        
52: R39         Licenses and Agreements (Details)                   HTML     69K 
53: R40         Legal Proceedings (Details)                         HTML     51K 
54: R41         LEASES - Company's right-of-use asset and lease     HTML     28K 
                liabilities (Details)                                            
55: R42         LEASES - components of lease expenses (Details)     HTML     42K 
56: R43         LEASES - maturities of the Company's operating      HTML     45K 
                lease liabilities (Details)                                      
57: R44         LEASES - Additional information (Details)           HTML    142K 
58: R45         RELATED PARTY TRANSACTIONS - Additional             HTML     35K 
                information (Details)                                            
59: R46         Subsequent Event (Details)                          HTML     23K 
61: XML         IDEA XML File -- Filing Summary                      XML    106K 
13: XML         XBRL Instance -- iova-20200630x10q_htm               XML   1.90M 
60: EXCEL       IDEA Workbook of Financial Reports                  XLSX     88K 
 9: EX-101.CAL  XBRL Calculations -- iova-20200630_cal               XML    113K 
10: EX-101.DEF  XBRL Definitions -- iova-20200630_def                XML    491K 
11: EX-101.LAB  XBRL Labels -- iova-20200630_lab                     XML    881K 
12: EX-101.PRE  XBRL Presentations -- iova-20200630_pre              XML    744K 
 8: EX-101.SCH  XBRL Schema -- iova-20200630                         XSD    133K 
62: JSON        XBRL Instance as JSON Data -- MetaLinks              254±   388K 
63: ZIP         XBRL Zipped Folder -- 0001104659-20-091526-xbrl      Zip    351K 


‘R7’   —   Condensed Consolidated Statements of Cash Flows


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.20.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended
Cash Flows from Operating Activities    
Net Loss $ (132,613) $ (84,501)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 19,949 12,272
Noncash lease expense 3,328 3,031
Depreciation and amortization 512 560
Gain on settlement of dispute   (336)
Amortization of premiums on investments (17) (2,430)
Changes in assets and liabilities:    
Prepaid expenses, other assets, and long-term assets (1,064) (515)
Operating lease liabilities (Right-of-use assets) (3,739) (2,651)
Accounts payable (7,096) 9,951
Accrued expenses and other liabilities 18,813 1,734
Net cash used in operating activities (101,927) (62,885)
Cash Flows from Investing Activities    
Maturities of short-term investments 216,678 263,102
Purchase of short-term investments (534,717) (201,129)
Purchase of property and equipment (5,612) (2,257)
Net cash (used in) provided by investing activities (323,651) 59,716
Cash Flows from Financing Activities    
Tax payments related to shares withheld for vested restricted stock awards (283) (95)
Proceeds from the issuance of common stock upon exercise of options 5,188 3,474
Proceeds from the issuance of common stock, net 567,393  
Net cash provided by financing activities 572,298 3,379
Net increase in cash, cash equivalents, and restricted cash 146,720 210
Cash, Cash Equivalents, and Restricted Cash, Beginning of Period 19,419 82,152
Cash, Cash Equivalents, and Restricted Cash, End of Period 166,139 82,362
Supplemental disclosure of non-cash investing and financing activities:    
Unrealized gain on short-term investments 97 414
Acquisitions of property and equipment included in accounts payable and accrued expense (5,212) $ (92)
Accrued offering costs in accrued expenses $ (393)  

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:8/6/208-K
For Period end:6/30/20
6/30/1910-Q
 List all Filings 


6 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/24  Iovance Biotherapeutics, Inc.     10-K       12/31/23   95:11M                                    Toppan Merrill Bridge/FA
 2/28/23  Iovance Biotherapeutics, Inc.     10-K       12/31/22   78:10M                                    Toppan Merrill Bridge/FA
 2/24/22  Iovance Biotherapeutics, Inc.     10-K       12/31/21   79:10M                                    Toppan Merrill Bridge/FA
 2/25/21  Iovance Biotherapeutics, Inc.     10-K       12/31/20   84:11M                                    Toppan Merrill Bridge/FA
 2/09/21  Iovance Biotherapeutics, Inc.     424B5                  1:799K                                   Toppan Merrill/FA
11/05/20  Iovance Biotherapeutics, Inc.     10-Q        9/30/20   62:7.8M                                   Toppan Merrill Bridge/FA


3 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/09/20  Iovance Biotherapeutics, Inc.     8-K:5,9     6/08/20   12:480K                                   Toppan Merrill/FA
 5/27/20  Iovance Biotherapeutics, Inc.     8-K:5,8,9   5/27/20   12:508K                                   Toppan Merrill/FA
 2/25/20  Iovance Biotherapeutics, Inc.     10-K       12/31/19   88:11M                                    Toppan Merrill/FA
Top
Filing Submission 0001104659-20-091526   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 10, 1:31:55.2am ET